Who is sponsoring NCT04702373?

NCT04702373 is sponsored by Carelon Research.

What drugs are being tested in NCT04702373?

Interventions in NCT04702373: passive range of motion exercise therapy.

What condition does NCT04702373 study?

NCT04702373 studies Congenital Heart Disease.

Is NCT04702373 still recruiting?

NCT04702373 is currently active, enrolled. Last updated 3 July 2024.

Last reviewed 2024-07-03 · How we verify

NCT04702373: T4G RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT

Active, enrolled Phase 3 Last updated 3 July 2024

What this trial tests

Phase 3 trial testing passive range of motion exercise therapy in Congenital Heart Disease in 144 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 February 2021

Primary endpoint
30 November 2024

30 December 2024

Quick facts

Lead sponsor	Carelon Research
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	144
Start date	23 February 2021
Primary completion	30 November 2024
Estimated completion	30 December 2024
Sites	10 locations across Canada, United States

Drugs / interventions tested

passive range of motion exercise therapy

Conditions studied

Congenital Heart Disease — all drugs for Congenital Heart Disease →

Sponsor

Carelon Research — full company profile →

Who can join

Under 35 Days, any sex, with Congenital Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase III randomized controlled trial of a passive ROM exercise program that will be performed in infants with HLHS and other single right ventricle anomalies following the Norwood procedure at PHN and Auxiliary Centers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The molecular mechanisms of cardiac development and related diseases.
Li Y, Du J, Deng S, Liu B, et al · · 2024 · cited 53× · PMID 39715759 · DOI 10.1038/s41392-024-02069-8
Prospects for precision genetic medicine in congenital heart disease.
Gelb BD. · · 2022 · cited 6× · PMID 36115276 · DOI 10.1016/j.gde.2022.101983

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease

Currently open trials in the same condition.

NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting

Other Carelon Research trials

Trials by the same sponsor.

NCT05268094 — Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) · NA · active not recruiting
NCT05312177 — Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS) · completed
NCT04475718 — Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women · NA · completed
NCT05287412 — Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children · active not recruiting
NCT04090697 — Use of Oxandrolone to Promote Growth in Infants With HLHS · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04702373 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carelon Research
Last refreshed: 3 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04702373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing